JP Morgan Maintains Overweight on Hims & Hers Health, Lowers Price Target to $33

Benzinga Newsdesk www.benzinga.com Negative 84.0%

Neg 84% Neu 0% Pos 0%

JP Morgan analyst Cory Carpenter maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $35 to $33.